SUMMARY Several drugs used for standard antihypertensive therapy may also interact with the lipoprotein metabolism. The following has been observed after 1 to 12 months of treatment. Various thiazide-type diuretics may significantly increase the potentially atherogenic serum low-densltylipoprotein cholesterol (LDL-C) and/or very-LDL-C-fractions, while the antiatherogenic high-density-lipoprotein cholesterol (HDL-C) is largely unchanged. Certain loop-diuretics also increase the LDL-C/HDL-C ratio and both types of diuretics elevated serum triglycerides (Tg) in some but not all studies. LDL-C was increased in diuretic-treated men and in chlorthalidone-treated postmenopausal women, but not in chlorthalidone-treated premenopausal women. The latter may be protected from this effect. Only two diuretics evaluated, namely indapamide and spironolactone, had no apparent influence on lipoproteins. Beta-blocker monotherapy may often increase Tg and slightly decrease HDL-C. The magnitude of these changes did not distinctly differ between highly cardioselective and nonselective beta-blockers, but it was less pronounced on beta-blockers than on those without intrinsic sympatholytic activity. Other sympatholytics such as reserpine, methyldopa, clonidine, debrisoquine, the alpha-beta-blocker labetalol, or the posts}naptic alpha-blocker, prazosin, did not affect or even slightly decrease Tg or total C, LDL-C, and very-LDL-C values. With combinations, a tendency for increased Tg and lower HDL-C was also apparent during thiazide-type diuretic-beta-blocker therapy. However, diuretic-induced increases in LDL-C were prevented or reversed by concomitant betablockade, but not by reserpine, methyldopa, or clonidine. Monotherapy with the potent direct vasodilator, carprazidil, improved blood pressure and significantly increased HDL-C. Prospective long-term studies are needed to clarify the course and the pathogenic and prognostic relevance of lipoprotein changes induced by certain diuretics or beta-blockers. In the hypertensive population, effective blood pressure control with diuretics, conventional sympatholytics, and, if necessary, hydralazines led to a distinct improvement of cardiovascular prognosis, although with questionable beneficial effect on the course of coronary heart disease.
H YPERTENSION and certain alterations in li-
poprotein metabolism are very important cardiovascular risk factors. In the hypertensive population, effective blood pressure control with diuretics, conventional sympatholytics, and, if necessary, hydralazines led to a distinct improvement of cardiovascular prognosis, although with questionable beneficial effect on the course of coronary heart disease. 1 ' 2 However, more recent observations suggested that the addition of beta-blockers to drug therapy may reduce the incidence of myocardial infarction in hypertensive patients. 3 This raised the question of whether the more conventional drug therapy had an unfavorable influence on a coronary risk factor other than high blood pressure, or whether beta-blockers exerted some beneficial effect not obtained with previous sympatholytics. One of the factors to be considered is the lipoprotein metabolism.
In some earlier studies, total serum levels of triglycerides and cholesterol only were measured during treatment with certain antihypertensive drugs. An interpretation is somewhat difficult, because variations in total serum lipid values per se may be less important correlates of atherogeneity than certain alterations in the pattern of blood lipoproteins. Based on epidemiologic findings, decreases in high-density-lipoprotein cholesterol (HDL-C) or increases in low-density-lipoprotein cholesterol (LDL-C) may both augment the risk for coronary heart disease; 4 -5 a similar tendency is suspected for elevated blood levels of triglyceride (Tg)-rich lipoproteins. 6 Moreover, in recent years it has become evident that several of the drugs used for standard antihypertensive therapy may in fact also interact with the lipoprotein metabolism. These observations are reviewed in the present report.
Diuretic Monotherapy Effects
Diuretics have long been the major antihypertensive drugs, and possible unfavorable interactions with factors other than blood pressure per se could, therefore, have a correspondingly great impact. The influence of a monotherapy with various diuretics on serum lipo- 14~18 ' M various thiazide-type diuretics may increase total cholesterol (C) slightly and, more important, may significantly increase LDL-C and/or very-low-density-lipoprotein cholesterol (VLDL-C). Except for one report 20 of a parallel rise in HDL-C, HDL-C and, when measured, HDL's major apoproteins A, and A 2 were largely unchanged.
12
" 19 ' 21 This supports the frequent occurrence of elevated LDL/HDL and total C/HDL ratios in thiazide-treated patients.
Loop diuretics, such as furosemide, the structurally related mefruside, and muzolimine also increased these ratios, due to mildly increased total or LDL-C and unchanged or even slightly decreased HDL-C values (table I) . 10 Gender may play a role in the interaction between certain diuretics and lipoproteins. Most observations were restricted to groups consisting largely or entirely of men. Therefore, chlorthalidone was chosen to investigate whether women may also be prone to develop diuretic-induced changes in serum lipoproteins. 19 The finding of a similar increase in total and LDL-C in postmenopausal women ( fig. 1 A critical aspect of any metabolic side-effect is its course over time. Based on the studies summarized in table 1, the tendency for increases in the potentially atherogenic LDL-C (or LDL-C + VLDL-C) fraction or Tg concentrations was quite similar between 1 and 12 months of. monotherapy with thiazide-type or certain loop diuretics ( fig. 3) . However, whether and to what extent such alterations may persist over years of treatment is presently unclear. Reports of unchanged or even slightly lower levels of total Tg and C in hypertensive men after they had been treated for 6 years with bendroflumethiazide 28 drochlorothiazide" may be related in part to dietary modifications and cannot exclude a reciprocal change in the LDL-C and HDL-C fractions. Although HDL-C values were listed in one of these reports, an interpretation is difficult because of an uncertain decay rate of HDL-C in pretreatment plasma samples kept for 4 years in frozen storage."
Possible Mechanisms Two major mechanisms are involved in the druginduced secondary hyperlipoproteinemias, namely, increased hepatic lipoprotein synthesis and disturbed lipoprotein catabolism. Thiazide-like diuretics, by inhibiting phosphodiesterase 29 and/or by causing mild sympathetic activation, 30 may increase cyclic AMP, thereby stimulating lipolysis. 31 Although this mechanism could well contribute to variations in serum triglycerides, there is no actually known pathway providing a link to the observed changes in serum LDL-C. In fact, the serum levels of lipoprotein-lipase and hepatic triglyceride lipase were unchanged in chlorthalidonetreated men. 32 Plasma volume and plasma insulin, glucose, or epinephrine levels were not altered following short-term diuretic treatment, and changes in LDL-C also did not correlate with some functional, biochemical , or endocrine effects of diuretics, such as variations in blood pressure, body weight, plasma potassium, uric acid, renin, aldosterone, or norepinephrine leve l s io. is, 19.21.24,33.34 j^ c o n stellation of increased LDL-C with an unchanged concentration of LDL's major protein component, apo-protein B, following monotherapy with ticrynafen 24 or chlorthalidone in men' 3> M was consistent with an increased cholesterol carrying capacity of the LDL-fraction. On the other hand, a tendency for parallel increases in LDL-C and apoprotein B was noted following treatment with chlorthalidone in postmenopausal women. 19 Therefore, a complex mechanism may be operative, and the relative importance of increased carrying capacity, synthesis, or catabolism of LDL-C needs to be clarified.
The relative lack of estrogen and progesterone in men and postmenopausal women may have a role. 35 In the rat, certain estrogens increased the binding sites for LDL in liver and adrenal cells, thereby enhancing the catabolism of LDL.
3 * 37 Estrogens may also increase the hepatic uptake of chylomicron remnants, which may in turn regulate liver VLDL synthesis and its subsequent conversion to LDL as a result of lipolysis. The possibility must be considered that certain diuretics may interfere with these pathways in men and postmenopausal women who are somewhat estrogendeficient."
The absence of lipoprotein alterations following short-term treatment with the diuretic-antihypertensive agent, indapamide (table I) 2 4 '" could not be explained by a different influence of this drug on the various biochemical or endocrine parameters that were monitored in our studies. On the other hand, it has to be considered that differences in the biochemical structure or dosages used could modify the influence of
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diuretic compounds on LDL-C. The methyl-substituted isoindoline part of indapamide differentiates this agent structurally from chlorthalidone, hydrochlorothiazide, furosemide, and ticrynafen. 38 Spironolactone, which also may have no effect on serum lipoproteins, 18 20 However, the similar increases in LDL-C following high-or low-dose (50 mg/dl) chlorthalidone treatment 14 or following lowdose clopamide therapy 21 suggest that drug dosage did not play a major role in the development of this sideeffect.
Beta-Blocker Monotherapy
Beta-blockers have become an important alternative to diuretics as Step 1 antihypertensive drugs, particularly in younger patients. Therefore, a careful evaluation of both beneficial and possible undesirable effects of beta-blocker monotherapy is of great practical importance. The influence of beta-blockers on serum lipoproteins and/or total lipids can be assessed by a comparative analysis of reports of a monotherapy in a minimal number of 12 subjects per study.
12 -1628 -3 *- 57 It is evident that such treatment is frequently associated with moderate increases in total and VLDL Tg (averaging about 25% and 40%, respectively) and a mild but nevertheless often statistically significant decrease in HDL-C (averaging about 10%) ( fig. 4) . These changes were similarly apparent at between 2 weeks and 1 year of beta-blocker monotherapy. On the other hand, total C and LDL-C were largely unchanged during beta-blocker treatment 12, 16, 28, 39, 41-46, 48, 49, 51, 53, 57 Whether and to what extent beta-blocker-induced increases in Tg and decreases in HDL-C'may persist beyond 1 year of treatment is presently unclear. In the two available long-term follow-ups, a rather mild and statistically insignificant increase in total Tg was noted following 5 to 6 years of pindolol or propranolol thera Py (fig-4 ) ; however, no measurements of HDL-C or other lipoprotein fractions were made. 28 -" The possibility was considered that different types of beta-blockers may vary in their effect on lipoprotein metabolism. A combined analysis of the published reports (see above) suggests that, at least in the usual clinical dosages used for antihypertensive therapy, highly cardioselective (beta,) and unselective (beta, + 2 ) beta-blockers cause quite similar changes in serum Tg and HDL-C (table 2) . On the other hand, blockers with intrinsic sympathomimetic activity (ISA) may tend to produce less hypertriglyceridemia and also have less influence on HDL-C than those without ISA. Finally, the pretreatment level of the lipids could play a role. No consistent relationship between the latter and beta-blocker-induced increases in total Tg is apparent from the available studies; the apparent tendency of changes in VLDL-Tg to follow (see refs. 12, 16, 28, 39-57 such a trend is difficult to judge because of limited data ( fig. 5 ).
There is no evidence for increased lipoprotein synthesis during beta-blocker therapy. The blood levels of the free fatty acids, blood glucose, and insulin, which represent the most important components for hepatic lipoprotein production, were reported to be unaltered or even decreased in most studies. 51 -**• 59 However, the catabolism of triglyceride-rich lipoproteins in plasma may be slightly disturbed. 45 -60 - 61 These lipoproteins are hydrolyzed intravascularly by a system of different lipolytic enzymes; 62 lipoprotein-lipase and hepatic triglyceride lipase play the "key roles." These enzymes are located at the capillary endothelium and can be measured in plasma only after the intravenous injection of heparin, which removes them from their binding to the capillary wall. 62 The postheparin lipolytic activity was noted to be reduced by beta- blockers. 45 -6061 Selective measurements of both enzymes revealed a decreased activity of lipoprotein lipase originating from adipose tissue and muscle. 62 These observations are complemented by the finding of a disturbed elimination of intravenously injected intralipid. 45 Therefore, a disturbed catabolism of triglyceride-rich lipoproteins in plasma due to impaired lipoprotein lipase activity may possibly explain the beta-blocker-induced hypertriglyceridemia. The reason for the reduced enzyme activity is at present unknown. However, the increased VLDL may in turn reduce the HDL concentration, 63 although additional contributing mechanisms are not excluded.
Monotherapy with Other Sympatholytics
Although diuretics and beta-blockers are both used widely as monotherapy, several sympatholytics are preferably prescribed as Step 2 antihypertensive agents, that is, in combination with a diuretic. Nevertheless, some studies have assessed the influence of a monotherapy with such sympatholytics on serum lipids or lipoproteins, and the findings help to complement the spectrum of interactions.
Based on the reports with a minimal number of 11 subjects per study, various commonly used sympatholytics may in general not interfere unfavorably with the lipid metabolism (table 3) . After 2 to 3 months of a monotherapy with the postsynaptic alpha-receptor blocker, prazosin, total Tg as well as total C, LDL-C, and VLDL-C were unchanged or sometimes even slightly decreased, while HDL-C was unaltered. 43 ' 64 "* 6 It has been speculated 64 that prazosin, through phosphodiesterase inhibition and consecutively increased cyclic AMP, could modulate the cholesterol metabolism and fatty acid synthesis in the liver. 67 Nevertheless, quite similar results as those with prazosin were also observed following short-term monotherapy with the combined alpha-beta-blocker, labetalol, or some agents that lower sympathetic nervous system activity centrally and/or peripherally (table 3) . More specifically, labetalol given for 3 weeks resulted in slightly decreased total C with unchanged HDL-C and Tg values; 40 short-term clonidine treatment slightly lowered total C; 64 and the postsynaptic sympathetic neuron blocker, debrisoquine, administered for 4 weeks, caused a similarly mild but significant reduction in total C, LDL-C, and VLDL-C and apoprotein B with unchanged HDL-C and apoprotein A, and A 2 levels (table 4). Moreover, 3 months of monotherapy with methyldopa induced a tendency for parallel decreases in total Tg and total C and HDL-C (table 3) . 46 Short-term combination treatment with the alpha-blocker, prazosin, and the beta-blocker, propranolol, was reported to blunt the HDL-C lowering effect of the latter, while combined alpha-beta-blockade with prazosin and pindolol slightly decreased the LDL-C and VLDL-C fractions. 43 With more prolonged treatment, values of total Tg and C were unaltered following up to 1 year of monotherapy with reserpine, 18 -68 methyldopa, 18 -69 or labetalol; 50 -70 LDL-C and HDL-C also were unchanged with labetalol. 50 The long-term effects of prazosin have not been reported. Clearly, additional information is necessary to ascertain these aspects and to evaluate whether there is any relevant difference between the effects on lipids of the sympathetic nervous system inhibitors, namely, the combined alpha-beta-blocker, labetalol, and prazosin. In the meantime, based on the lipoprotein profile there is no convincing evidence that one of these sympatholytics should be preferred over the others for the treatment of hypertension.
Combination of Diuretics with Beta-Blockers or Other Sympatholytics
Although therapeutic intervention with diuretics, conventional sympatholytics, and, if necessary, hydralazines failed to distinctly reduce myocardial infarction in hypertensive patients, 1 ' 2 there is now some evidence that the introduction of beta-blockers into antihypertensive pharmacotherapy may produce such a beneficial effect. 3 This also elicits an interest in the possible lipid-related interactions between diuretics and conventional sympatholytics, as opposed to diuretics and beta-blockers. Reserpine and methyldopa are probably the two sympatholytics used most widely in the prebeta-blocker era. Clonidine arrived in the 1960s. In a series of observations over 2 to 12 months, reserpine, 1418 methyldopa, 18 -33 and clonidine 64 failed to antagonize the increases in total and/or LDL-C induced by preexisting or concomitant thiazide-type diuretic therapy. Nevertheless, certain authors, 43 whose report of unchanged serum lipoproteins following short-term hydrochlorothiazide monotherapy contrasts with most others, also described unchanged total Tg and C values following 3 years of combined hydrochlorothiazide-methyldopa treatment.
Studies of combined therapy with a diuretic and the postsynaptic alpha-blocker, prazosin, led to variable results. When prazosin was added to a preexisting regime with chlorthalidone or other diuretic, a tendency for higher HDL-C with unchanged LDL-C and stable or somewhat lower Tg levels were noted. 7 ' n However, the addition of polythiazide to a preexisting prazosin therapy resulted in a significant increase in total C. 64 In considering combination treatment with a thiazide-type diuretic and beta-blocker, a separate look at LDL-C on the one hand, and Tg and HDL-C on the other, may be helpful. In two separate studies performed in our laboratory, the increases in LDL-C seen with diuretic monotherapy were prevented or reversed by the concomitant administration of a beta-blocker. One study was made in 17 hypertensive men. 21 A significant (p < 0.025) increase in serum LDL-C that occurred during monotherapy with clopamide was no longer present 4 weeks following the addition of the beta-blocker pindolol ( fig. 6) . A similar finding was obtained in an entirely different group of 18 hypertensive patients ( fig. 7) .
M In 11 of them, a 22% increase (p < 0.001) in serum LDL-C during chlorthalidone monotherapy was restored to control values following 6 weeks of combination treatment with chlorthalidone and a beta-blocker (propranolol in nine and atenolol in two cases). In the remaining seven patients who were studied with an inverse sequence of drug administration, LDL-C was unaltered following 6 to 24 weeks of combination treatment with chlorthalidone and a betablocker (propranolol in four patients, atenolol in two, and oxprenolol in one) but was increased by 41% (p < 0.05) 6 weeks following withdrawal of the betablocker. These findings are supported by the stable total and/or LDL-C values in some short-term 16 73~7 ? or long-term 76 studies with different thiazide-type'diuretics and beta-blockers.
In contrast, the characteristic constellation during beta-blocker monotherapy, namely, a tendency for slightly increased total Tg and VLDL-Tg and mild decreases in HDL-C was sometimes also apparent during combination treatment with thiazide-type diuretics. 
Vasodilators
When hypertension does not satisfactorily respond to combination treatment with a diuretic and a betablocker or other sympatholytics, a three-drug regimen including a vasodilator is usually prescribed. While no information on the effect of such triple therapy on serum lipoproteins was found, very few studies have assessed the influence of vasodilator monotherapy. In an early investigation, the conventional direct vasodilator, hydralazine, had no effect when given in today's usually clinical dosage of 100 to 150 mg/day, but reduced total serum C by 10% to 15% when larger doses of 300 to 800 mg/day were administered. 77 Recently, the desirable constellation of improved blood pressure levels and increased serum HDL-C was observed in hypertensive men treated for 4 months with the new potent direct vasodilator, carprazidil (table 5). The possibility that antihypertensive agents with direct vasodilating properties may also favorably modify the serum lipoproteins may be of practical interest.
Relevance and Outlook
At the present stage, any of the lipoprotein changes induced by diuretics or other antihypertensive agents should be categorized as biochemical side-effects and no more. 7 * However, clarification of their possible pathogenic and prognostic relevance is needed. In the Multiple Risk Factor Intervention Trial, 79 the failure of coronary heart disease mortality to decrease in some patients receiving antihypertensive pharmacotherapy could not be explained by altered serum lipoproteins. Although this points to other contributory factors, a disturbed lipoprotein metabolism, when it occurs, could nevertheless play a potentially aggravating role. Therefore, long-term studies are required to delineate whether an altered lipoprotein constellation during monotherapy with various diuretics or beta-blockers, or combination treatment with diuretics and certain sympatholytic agents, may cause an increased risk for coronary heart disease and, thereby, partly offset the beneficial cardiovascular effects of lowered blood pressure. In the meantime, it is of clinical interest that premenopausal women may often be "protected" from the development of diuretic-induced increases in serum LDL-C, that indapamide may often not cause such a change in men, and that the concomitant administration of certain beta-blockers appears to prevent or reverse this side-effect of some diuretic agents in men or postmenopausal women.
